A diagnostic algorithm based on a simple clinical prediction rule for the diagnosis of cranial giant cell arteritis

*Michael Czihal¹, *Christian Lottspeich¹,², Christoph Bernau¹, Theresa Henke¹, Ilaria Prearo¹, Marc Mackert³, Siegfried Priglinger³, Claudia Dechant⁴, Hendrik Schulze-Koops⁴, Ulrich Hoffmann¹

¹Division of Vascular Medicine, Medical Clinic and Policlinic IV
²Interdisciplinary Sonography Center, Medical Clinic and Policlinic IV
³Department of Ophthalmology
⁴Division of Rheumatology and Clinical Immunology, Medical Clinical and Policlinic IV; Hospital of the Ludwig-Maximilians-University, Munich, Germany

*shared first authorship

Abstract: Background: Risk stratification based on pre-test probability may improve the diagnostic accuracy of temporal artery high-resolution compression sonography (hrTCS) in the diagnostic workup of cranial giant cell arteritis (cGCA). Methods: A logistic regression model with candidate items was derived from a cohort of patients with suspected cGCA (n = 87). The diagnostic accuracy of the model was tested in the derivation cohort and in an independent validation cohort (n = 114) by receiver operator characteristics (ROC)-analysis. The clinical items were composed to a clinical prediction rule, integrated into a stepwise diagnostic algorithm together with CRP-values and hrTCS-values. Results: The model consisted of 4 clinical variables (age > 70, headache, jaw claudication, anterior ischemic optic neuropathy). The diagnostic accuracy of the model for discrimination of patients with and without a final clinical diagnosis of cGCA was excellent in both cohorts (AUC 0.96 and AUC 0.92, respectively). The diagnostic algorithm improved the positive predictive value of hrCTS substantially. Within the algorithm, 32.8% of patients (derivation cohort) and 49.1% (validation cohort) would not have been tested by hrTCS. None of these patients had a final diagnosis of cGCA. Conclusion: A diagnostic algorithm based on a clinical prediction rule improves the diagnostic accuracy of hrTCS.

Keywords: Giant cell arteritis; anterior ischemic optic neuropathy; clinical prediction rule; diagnostic algorithm; C-reactive protein; temporal compression sonography; ultrasound.

1. Introduction

With an estimated lifetime risk of at 1% for women and 0.5% for men for developing the disease, giant cell arteritis (GCA) is the most common systemic vasculitis [1]. Diagnostic imaging nowadays plays an important role in the diagnosis of GCA. For the diagnostic workup of suspected cranial GCA (cGCA), colour duplex sonography (CDS) of the temporal ± axillary arteries is recommended as the first line imaging test [2-4]. High resolution sonography of the cranial arteries has been shown to accurately discriminate patients with and without cGCA [5-7]. However, recent evidence suggests that arteriosclerotic wall thickening may impair specificity of this diagnostic test [8,9]. In the absence of a disease-specific biomarker, the C-reactive protein (CRP), offering high diagnostic sensitivity but low specificity, is recommended by current guidelines for the evaluation of suspected GCA [3].

Beyond test accuracy, the predictive value of a diagnostic method is substantially influenced by pre-test probability which is determined by the prevalence of the disease in the studied population [10]. Therefore, clinical assessment of pre-test probability is of outstanding importance in order to optimize test performance. Current recommendations suggest imaging test interpretation based on clinical pre-test probability [2-4]. In clinical practice, assessment of pre-test probability for GCA is usually done by implicit (unstructured) clinical judgement, but several clinical prediction rules have been developed and in part validated in order to perform explicit (structured) pre-test probability assessment. So far, none of these clinical prediction rules have gained broad acceptance for clinical use. While the 2018 EULAR recommendations for the management of the large vessel vasculitides do not support the use of any prediction rule [3], the 2020 British Society for Rheumatology guideline on diagnosis and treatment of
GCA for the first time mention clinical prediction rules as being potentially useful for assisting clinicians in the estimation of GCA-probability [4].

In order to optimize test performance of high-resolution compression sonography (hrTCS) of the temporal arteries in the diagnostic workup of suspected cGCA, the present study aimed at establishing and validating a clinical prediction rule and integrating the clinical prediction role together with the CRP-values in a clinically useful diagnostic algorithm.

2. Patients and Methods

2.1. Cohort characteristics
The study, approved by the local ethics committee (project number: 18-502), was based on two independent cohorts of consecutive patients with suspected cGCA evaluated at a single interdisciplinary vasculitis center [7,9]. All patients in both cohorts underwent a sonographic study of the temporal and axillary arteries, including hrTCS of the temporal arteries. The optimal cut-off of temporal artery wall thickness (sum of the near and far arterial wall) had previously been determined at ≥ 0.7 mm (sensitivity and specificity of 85% and 95%, respectively) [7]. In the first cohort, published in 2017, diagnosis of cGCA was based on fulfilment of > 3 American College of Rheumatology classification criteria and/or a positive temporal artery biopsy (TAB) [7,11]. In the second cohort, published in 2020, a diagnosis of cGCA was established when at least three of the five following criteria were fulfilled: (1) age ≥ 50 years; (2) typical cranial symptoms (new onset, persisting headache, jaw claudication, temporal artery tenderness); (3) unequivocal symptoms of polymyalgia rheumatica; (4) ESR > 30 mm per 1 hour (reference range ≤ 20 mm per 1 hour) or C-reactive protein ≥ 1 mg/dl; (normal range < 0.5 mg/dl); (5) typical hypoechogenic wall thickening (Halo) of the superficial temporal arteries or positive TAB [5,9]. In both cohorts, extracranial GCA was diagnosed based on typical imaging findings in CDS of the axillary arteries (hypoechogenic circumferential wall thickening of ≥ 1.2 mm) and non-invasive cross sectional imaging (magnetic resonance imaging or positron emission tomography/computed tomography) [7,9].

2.2. Derivation of the clinical model
We performed a literature review to identify clinical symptoms and signs predictive for a diagnosis of cGCA [12-30]. We analysed the prevalence of potential candidate items in the first cohort, comprising 92 patients referred to our institution with suspected GCA (cranial and/or extracranial) between 10/2014 and 10/2015 [7]. CRP-values were available for 87 of 92 patients who were included in the present analysis (26 patients with a final clinical diagnosis of cGCA). Univariate comparisons between patients with and without a final diagnosis of cGCA were made using χ² test (categorical variables) and Mann-Whitney-U test (continuous variables). Based on the literature review, results of the univariate analysis, and subject matter expertise, various logistic regression models consisting only of categorical variables were set up. Clinical symptoms and objective ophthalmological findings were considered for modelling, whereas laboratory values and vascular imaging findings were not. In order to keep the clinical model as simple as possible, continuous variables were not included. For further analysis, the model with the lowest Akaike’s information criterion (AIC) was used. The diagnostic accuracy of this model for discrimination of patients with and without a final diagnosis of cGCA in the derivation cohort were assessed using receiver-operator-characteristics (ROC-) analysis.

2.3. Validation of the clinical model in an independent cohort
Based on the results found in the derivation cohort, we validated the logistic model in the second cohort. This validation cohort consisted of 114 patients referred for sonography of the temporal and axillary arteries, including hrTCS of the temporal arteries as part of the diagnostic workup of acute arterial perfusion disorders of the eye (30 patients with a final diagnosis of cGCA) [9].

2.4. Stepwise diagnostic algorithm integrating the clinical model, C-reactive protein and hrTCS
We integrated the items from the final clinical model rule together with the CRP-values and hrTCS (temporal artery wall thickness cut-off of ≥ 0.7 mm) into a stepwise diagnostic algorithm, aiming on stratification of pre-test probability of cGCA in a low risk vs. a non-low risk category. Based on current evidence, the cut-off of the CRP was set at ≥ 2.5 mg/dl [12,31,32]. The diagnostic accuracy of the diagnostic algorithm for the diagnosis/exclusion of cGCA in both cohorts was assessed by using 2x2 contingency tables.
2.5. Statistical analysis

All steps of statistical analysis, as stated above, were performed with the R software for statistical computing (R Development Core Team, Vienna, Austria). Two-sided p-values <0.05 were considered significant. Results for categorical variables are presented as absolute numbers with percentages, and continuous variables are displayed as mean ± standard deviation (SD).

3. Results

3.1. Derivation of the clinical model

The clinical characteristics of patients with (n = 26) and without (n = 61) a final clinical diagnosis of cGCA in the derivation cohort are compared in Table 1.

| Table 1. Comparison of clinical characteristics of patients with and without a final diagnosis of cGCA in both cohorts. |
|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| Cohort 1, final diagnosis of cGCA n = 26 | Cohort 1, final diagnosis not cGCA n = 61 | Cohort 2, final diagnosis of cGCA n = 30 | Cohort 2, final diagnosis not cGCA n = 84 |
| Age, years (mean ± SD) | 73.2 (9.2) | 66.1 (11.2) | 77.5 (6.7) | 73.6 (10.2) |
| Female sex (n, %) | 15 (57.7) | 33 (54.1) | 19 (63.3) | 40 (47.6) |
| New onset headache (n, %) | 21 (80.8) | 11 (18) | 19 (63.3) | 13 (15.5) |
| Jaw claudication (n, %) | 16 (61.5) | 2 (3.3) | 18 (60) | 0 |
| Amaurosis fugax (n, %) | 4 (15.4) | 7 (11.5) | 2 (6.7) | 4 (4.8) |
| Permanent sight loss (n, %) | 19 (73.1) | 18 (29.5) | 30 (100) | 84 (100) |
| AION (n, %) | 16 (61.5) | 7 (11.4) | 28 (93.3) | 26 (31) |
| Bilateral AION (n, %) | 3 (11.5) | 1 (1.6) | 6 (20) | 3 (3.6) |
| PMR (n, %) | 10 (38.5) | 21 (34.4) | 6 (20) | 1 (1.2) |
| Constitutional symptoms (n, %) | 12 (46.2) | 19 (31.1) | 13 (43.3) | 4 (4.8) |
| C-reactive protein (mg/dl, mean ± SD) | 5.2 (5.3) | 4.2 (5.6) | 5.1 (5.7) | 0.8 (0.9) |
| Temporal artery biopsy performed (n, %) | 13 (50) | 6 (9.8) | 8 (26.7) | 9 (10.7) |
| Temporal artery biopsy positive (n, %) | 10 (38.5) | 0 | 5 (16.7) | 0 |

AION, anterior ischemic optic neuropathy; PMR, polymyalgia rheumatica.

3.2. Validation of the logistic model in an independent cohort

The clinical characteristics of patients with (n = 30) and without (n = 84) a final clinical diagnosis of cGCA in the validation cohort are listed in Table 1. According to ROC-analysis, the logistic model exhibited an area under the curve of 0.92 for correct classification of the final clinical diagnosis (cGCA vs. alternative diagnosis) in the validation cohort.
3.3. Stepwise diagnostic algorithm integrating the clinical model, C-reactive protein and hrTCS

Based on the above mentioned results, the four clinical parameters were arranged to a clinical prediction rule; the score’s items and the relative weightings chosen are listed in Table 2.

| Variable                              | Description | Score |
|---------------------------------------|-------------|-------|
| Age (years)                           | < 70 years  | 0     |
|                                       | > 70 years  | 1     |
| New onset persistent headache         | No          | 0     |
|                                       | Yes         | 1     |
| Jaw claudication                      | No          | 0     |
|                                       | Yes         | 1     |
| Permanent vision impairment due to AION | No      | 0     |
|                                       | Unilateral  | 1     |
|                                       | Bilateral   | 2     |

| Score (range 0-6)                      | Low clinical probability | ≤ 1 point |
|                                       | High clinical probability | > 2 points |

AION, anterior ischemic optic neuropathy

The relative distribution of patients and the proportion of patients with a final diagnosis of cGCA in different score categories are shown in Figure 1. Given the very low prevalence of cGCA in patients with a score of 0 or 1 (3.8%), these score categories were classified as low clinical probability, whereas the score categories ≥ 2 (prevalence of cGCA 79.4%) were categorized as non-low clinical probability.

Figure 1. Prevalence of patients with and without a final diagnosis of cGCA in different point categories of the clinical score in the derivation cohort (Panel A) and the validation cohort (Panel B).
The proposed diagnostic algorithm suggests hrTCS for all patients with non-low clinical probability (score ≥ 2), irrespective of CRP-values. Patients with low clinical probability (score < 2) are further stratified according to the CRP-values. In patients with CRP-values below the cut-off of ≥ 2.5 mg/dl a diagnosis of cGCA is rejected without sonographic imaging, whereas patients with CRP-values ≥ 2.5 mg/dl are assigned to undergo hrTCS (Figure 2).

Figure 2. Setup of the diagnostic algorithm integrating the clinical score, a CRP cut-off of ≥ 2.5 mg/dl in patients with low clinical probability, and hrTCS in patients with low clinical probability exhibiting CRP-values above the cut-off of ≥ 2.5 mg/dl, as well as in all patients with non-low clinical probability regardless of CRP-values. Patients with low clinical probability and a CRP-value < 2.5 mg/dl are not assigned to undergo sonographic imaging.

3.4. Performance of the diagnostic algorithm in the derivation cohort
A cut-off of ≥ 2 divided the derivation cohort in 53 patients (60.9%) with low clinical probability and 34 patients (39.1%) with non-low clinical probability (Figure 3). According to the diagnostic algorithm, 25 patients with low clinical probability (score < 2) and CRP-values ≥ 2.5 mg/dl were assigned to hrTCS (2 patients with a final diagnosis of cGCA, one of whom with a negative hrTCS-study). Twenty-eight patients (32.2% of the overall cohort) with low clinical probability and CRP-values < 2.5 mg/dl would not have been tested with sonographic imaging and none of these patients had a final clinical diagnosis of cGCA. In the subgroup of 34 patients with non-low clinical probability, 24 patients were finally diagnosed with cGCA (21 patients with positive hrTCS) and 10 patients were classified as alternative diagnoses (3 patients with positive hrTCS).

3.5. Performance of the diagnostic algorithm in the validation cohort
A cut-off of ≥ 2 divided the derivation cohort in 60 patients (52.6%) with low clinical probability and 54 patients (47.4%) with non-low clinical probability (Figure 3). According to the diagnostic algorithm, only 4 patients with low clinical probability (score < 2) and CRP-values > 2.5 mg/dl were assigned to hrTCS (one patient with a final diagnosis of cGCA who had a positive hrTCS-study, three patients with a negative hrTCS-study finally classified as alternative diagnoses). Fifty-six patients (49.1%) with low clinical probability and CRP-values < 2.5 mg/dl would not have been tested with sonographic imaging and none of these patients had a final clinical diagnosis of cGCA. In the subgroup of 54 patients with non-low clinical probability, 29 patients were finally diagnosed with cGCA (all with a positive hrTCS) and 25 patients were classified as alternative diagnoses (5 patients with positive hrTCS).
3.6. Test performance of hrTCS dependent on pre-test probability

The test performance of hrTCS in different point categories of the clinical prediction rule are summarized in Table 3 (both cohorts taken together). When applied in the derivation cohort on all patients with low clinical probability (n = 53), hrTCS exhibited a positive predictive value (PPV) and negative predictive value (NPV) of 50% and 98.4%, respectively. When applied only in patients with low clinical probability and CRP-values of at least 2.5 mg/dl (n = 25), the PPV and NPV were 100% and 95.8%. In patients with non-low clinical probability (n = 34), hrTCS had a PPV and NPV of 91.3% and 72.7%. When applied in the validation cohort on all patients with low clinical probability (n = 60), hrTCS exhibited a PPV and NPV of 11.1% and 100%, respectively. Noteworthy, 8 out of 9 patients from the derivation cohort with low clinical probability but hrTCS-values above the reference range were clinically classified as not having cGCA. Four patients with low clinical probability and CRP-values of at least 2.5 mg/dl were correctly classified by hrTCS. In patients with non-low clinical probability (n = 54), hrTCS had a PPV and NPV of 85.3% and 100%.

Table 3. Positive and negative predictive value of hrTCS in different score categories (both cohorts together, n = 201).

| SCORE | Proportion of patients (n, %) | Prevalence of cGCA (n, %) | PPV | NPV |
|-------|------------------------------|---------------------------|-----|-----|
| 0     | 39 (18.8)                    | 1 (2.6)                   | 50  | 100 |
| 1     | 74 (35.7)                    | 2 (2.7)                   | 11.1| 98.4|
| 2     | 39 (18.8)                    | 11 (28.2)                 | 69.2| 92.3|
| 3     | 17 (8.2)                     | 10 (58.8)                 | 75  | 80  |
| 4     | 14 (6.8)                     | 14 (100)                  | 100 | *   |
| 5     | 13 (6.3)                     | 13 (100)                  | 100 | *   |
| 6     | 5 (2.4)                      | 5 (100)                   | 100 | *   |

*In both cohorts, all patients with a score of 4-6 had a positive hrTCS-study and were finally diagnosed with cGCA.

3.7. Extracranial GCA

Extracranial GCA was diagnosed in 14 patients of cohort 1 (16.1%), including 7 patients with concomitant cGCA and 7 patients with isolated extracranial involvement (no cranial symptoms, normal temporal arteries by hrTCS). Twelve out of 14 patients with extracranial GCA had a positive CDS-study of the axillary arteries with depiction of a hypoechoic circumferential wall thickening (6 of 7 patients with and without concomitant cGCA, respectively). The two remaining patients had cross sectional imaging evidence of extracranial GCA. Five out of 14 patients with extracranial GCA had a score of 0 or 1, all of them displaying typical findings of extracranial GCA in CDS of the axillary arteries. Two of these 5 patients had CRP-values below 2.5 mg and thus would not have undergone imaging within the diagnostic algorithm. Both patients complained typical arm claudication but no cranial symptoms. Nine out of 14 patients with extracranial GCA had a score ≥ 2.
Extracranial GCA was diagnosed in 6 patients of cohort 2 (5.2%), all of whom had typical symptoms and sonographic signs (temporal artery wall thickness in hrTCS > 0.7 mm) of cGCA. The clinical score was above 2 in all patients (range 3-6 points). A typical hypoechoic circumferential wall thickening of the axillary arteries was found in 5 of 6 patients, and one patient had typical wall thickening of the vertebral arteries only.

4. Discussion

Based on our results, we propose a simple clinical prediction rule for the diagnosis of cGCA. Our model is based on biographic information (age > 70 [12,14,20,21,23,24,25]), clinical symptoms which can be easily assessed by taking a careful medical history (headache [14-16,20,22,25], jaw claudication [12,14-16,18-25]), and a specific funduscopic finding obtained in patients presenting with visual impairment (AION [15]). We used the item AION in our model, as AION is by far the most common cause of permanent visual impairment resulting from cGCA [33]. Our clinical prediction rule discriminated cGCA from alternative diagnoses with high diagnostic accuracy in the derivation cohort as well as in the independent validation cohort.

A stepwise diagnostic algorithm incorporating both the clinical prediction rule and a sensitive but nonspecific laboratory biomarker such as the CRP is helpful in identifying patients in whom a final clinical diagnosis of cGCA may even be excluded without imaging. According to the available evidence, we chose a CRP-value of ≥ 2.5 mg/dl as threshold for performing hrTCS in patients stratified as having low risk in the clinical model [12,31,32]. One third of patients in the derivation cohort and almost half of the patients in the validation cohort were deemed to have low clinical probability according to the prediction rule and had CRP-values below 2.5 mg/dl. None of these patients received a final diagnosis of cGCA. Such an approach may reduce resource utilisation by reducing fast-track specialist referral for diagnostic imaging. Compared to a diagnostic strategy applying imaging in all suspected cases, this approach reduces the rate of false positive sonographic studies in patients with low clinical probability. Potential harms resulting from empiric high dose corticosteroid/biological treatment in false positive cases thus may be avoided in a considerable number of patients.

Two patients finally diagnosed with isolated extracranial GCA from cohort 1 would not have been tested by imaging within the diagnostic algorithm. Both patients suffered from arm claudication and had typical findings of extracranial GCA in axillary artery CDS. In view of this finding, it must be noted that the clinical prediction rule is not intended to diagnose or exclude extracranial GCA. Given the highly variable clinical presentation of extracranial GCA, incorporation of symptoms of extracranial disease into a clinical prediction rule would result in a loss of simplicity, making the scoring system less useful for clinical practice.

The diagnostic algorithm results in an enrichment of patients with a final diagnosis of cGCA in the category of patients classified as having a non-low clinical probability, thereby increasing the PPV of hrTCS in this subgroup. Few false positive findings remained in both cohorts analyzed, all in patients with a score of 2 or 3. Obviously, there remains a need for optimizing the sonographic protocol by means of establishing cut-off values of temporal artery wall thickness stratified according to age, sex, and cardiovascular risk profile [8,9]. Alternative ways of imaging assessment (e.g. considering a test as positive only in case of at least 2 affected temporal artery segments; semiquantitative scoring systems of temporal artery wall thickness) should be evaluated in this context [9,34].

Several clinical prediction rules have been built and tested for prediction of cGCA, mainly integrating clinical findings and laboratory markers to predict the probability of a positive temporal artery biopsy in ophthalmology settings [12,15,18,20,22,24,25]. Some authors provided calculators for prediction of the probability of cGCA [26,27]. Niederkohr et al. in 2005 proposed a decision analytic approach in order to give objective recommendations on whether or not to perform TAB uni- or bilaterally [16]. In 2020, Monti and co-workers presented a combined clinical (cranial ischemic symptoms, polymyalgia rheumatica, elevated acute phase reactants) and sonographic (intima media thickness above established reference values in the temporal arteries and axillary arteries, bilateral halo of the temporal arteries and axillary arteries) score based on data from the TABUL-study. The score allowed identification of patients with a positive TAB with fair diagnostic accuracy (AUC 0.77) [50]. El-Dairi et al. and, more recently, Laskou et al. proposed diagnostic algorithms based on clinical probability scores derived from single center cohorts [21,28]. Of note, Laskou et al. were the first to use a clinical diagnosis, taking into account the clinical course over time [28]. Subsequently, this Southend pretest probability score, stratifying fast-track referral patients into low-risk, intermediate-risk and high-risk probability category based on 17 items, was shown to enhance the test performance of temporal/axillary artery sonography [29].
However, to the best of our knowledge, a formal stepwise algorithm for the diagnostic management of cGCA has not been established and validated so far. Only limited data suggest a promising role of diagnostic algorithms starting with a clinical prediction rule in rheumatic diseases in general, such as axial spondylarthropathies [35]. However, a positive effect of clinical prediction rules on process outcomes has been documented for various medical conditions, (e.g., reduction of additional diagnostic testing, early discharge, symptom improvement) [36]. A stepwise diagnostic concept starting with a clinical prediction rule is well established in current guideline recommendations on the management of one of the most common cardiovascular disorders, namely venous thromboembolism [37]. cGCA shares some important characteristics with venous thromboembolism, e.g. the acute onset and the risk of severe complications if undiagnosed or left untreated, the established use of a sensitive but nonspecific biomarker, and a sonographic imaging test as the diagnostic standard.

We acknowledge some limitations of our study. Both cohorts were retrospectively analysed, and the final diagnosis of cGCA vs. alternative diagnoses was based on clinical judgement and not on histology of the temporal arteries in most of our cases. TAB was performed only in a minority of patients, reflecting the paradigm change towards an imaging-based diagnostic approach which took place in the last decade. The validation cohort consisted of preselected patients suffering from acute-onset, permanent visual impairment. Since 2014, we have been using hrTCS in addition to CDS of the temporal arteries for the diagnostic workup of suspected cGCA. Whether our results can be transferred to other study populations and to other sonographic approaches (CDS only, intima-media-thickness measurements of the cranial arteries) remains to be investigated.

5. Conclusions.

In summary, we propose a simple clinical prediction role which, integrated into a stepwise algorithm, exactly discriminates patients with cGCA from patients with alternative diagnoses. This strategy implies a significant increase of diagnostic confidence both in primary and in specialist care, when evaluating a patient with low clinical probability and only slightly elevated CRP-values. Provided that the diagnostic yield of our diagnostic algorithm can be confirmed in prospective validation cohorts, a prospective management study to verify the safety and efficacy of the algorithm seems to be justified.

Author Contributions: Conceptualization, M.C., C.L.; methodology, M.C., C.L., C.B., U.H.; software, C.B.; validation, M.M., S.P., C.D., H.S.-K., U.H.; formal analysis, M.C., C.L., C.B.; investigation, M.C., C.L., T.H., I.P., M.M., C.D.; resources, S.P., H.S.-K., U.H.; data curation, M.C.; writing—original draft preparation, M.C., C.L.; writing—review and editing, M.C., C.L., C.B., T.H., I.P., M.M., S.P., C.D., H.S.-K., U.J.; visualization, M.C., C.L.; supervision, M.C.; All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the Medical Faculty of the Ludwig-Maximilians-University, Munich, Germany (project number: 18-502).

Informed Consent Statement: Patient consent was waived by the Ethics Committee due to retrospective analysis of irreversibly anonymized data.

Data Availability Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Crowson CS, Matteson EL, Myasoedova E, Michel CJ, Ernste FC, Warrington KJ, Davis JM 3rd, Hunder GG, Therneau TM, Gabriel SE. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63(3):633-9.

2. Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D, Brouwer E, Cimmino MA, Clark E, Dasgupta B, Diamantopoulos AP, Direskeneli H, Iagnocco A, Klink T, Neill L, Ponte C, Salvarani C, Slart RHJA, Whitlock M, Schmidt WA. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018;77(5):636-643.

3. Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, Cassie R, Cid MC, Dasgupta B, Dejaco C, Hatemi G, Hollinger N, Mahr A, Mollan SP, Mukhtyar C, Ponte C, Salvarani C, Sivakumar R, Tian X, Tomasson G, Turesson C, Schmidt W, Villiger PM, Watts R, Young C, Luqmani RA. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19-30.

4. Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, Mahr A, Mukhtyar C, Reynolds G, de Souza AWS, Brouwer E, Bukhari M, Buttgerieit F, Byrne D, Cid MC, Cimmino M, Direskeneli H, Gilbert K, Kermani TA, Khan A, Lanyon P, Luqmani R, Mallen C, Mason JC, Matteson EL, Merkel PA, Mollan S, Neill L, Sullivan EO, Sardovici M, Schmidt WA, Watts R, Whitlock M, Yacyshyn E, Ytterberg S, Dasgupta B. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology (Oxford). 2020;59(3):e1-e23.

5. Schafer VS, Juche A, Ramiro S, Krause A, Schmidt WA. Ultrasound cut-off values for intima-media thickness of temporal, facial and axillary arteries in giant cell arteritis. Rheumatology (Oxford). 2017 Sep 1;56(9):1479-1483.

6. Ješe R, Rotar Ž, Tomšič M, Hočevar A. The cut-off values for the intima-media complex thickness assessed by colour Doppler sonography in seven cranial and aortic arch arteries. Rheumatology (Oxford). 2020 Sep 18:kea578.

7. Czihal M, Schröttle A, Baustel K, Lottspeich C, Dechant C, Treitl KM, Treitl M, Schulze-Koops H, Hoffmann U. B-mode sonography wall thickness assessment of the temporal and axillary arteries for the diagnosis of giant cell arteritis: a cohort study. Clin Exp Rheumatol. 2017;35 Suppl 103(1):128-133.

8. De Miguel E, Beltran LM, Monjo I, Deodati F, Schmidt WA, Garcia-Puig J., Atherosclerosis as a potential pitfall in the diagnosis of giant cell arteritis. Rheumatology (Oxford). 2018;57(2):318-321.

9. Czihal M, Köhler A, Lottspeich C, et al. Temporal artery compression sonography for the diagnosis of giant cell arteritis in elderly patients with acute ocular arterial occlusions. Rheumatology (Oxford). 2020 Oct 30 (Online ahead of print).

10. Griner PF, Mayewski RJ, Mushlin AI, et al. Selection and interpretation of diagnostic tests and procedures. Principles and applications. Ann Intern Med 1981;94:557-92.

11. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122-8.

12. Hayreh SS, Podhajsky PA, Raman R, Zimmerman B. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol. 1997;123(3):285-96.
13. Gabriel SE, O’Fallon WM, Achkar AA, Lie JT, Hunder GG. The use of clinical characteristics to predict the results of temporal artery biopsy among patients with suspected giant cell arteritis. J Rheumatol. 1995;22(1):93-6.

14. Rodriguez-Valverde V, Sarabia JM, González-Gay MA, Figueroa M, Armona J, Blanco R, Fernández-Sueiro JL, Martínez-Taboada VM. Risk factors and predictive models of giant cell arteritis in polymyalgia rheumatica. Am J Med. 1997;102(4):331-6.

15. Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA. 2002;287(1):92-101.

16. Niederkohr RD, Levin LA. Management of the patient with suspected temporal arteritis a decision-analytic approach. Ophthalmology. 2005 May;112(5):744-56.

17. Rodríguez-Pla A, Rosselló-Urgell J, Bosch-Gil JA, Huguet-Redecilla P, Vilardeull-Tarres M. Proposal to decrease the number of negative temporal artery biopsies. Scand J Rheumatol. 2007;36(2):111-8.

18. Moutray TN, Williams MA, Best JL. Suspected giant cell arteritis: a study of referrals for temporal artery biopsy. Can J Ophthalmol. 2008;43(4):445-8.

19. Rieck KL, Kermani TA, Thomsen KM, Harmsen WS, Karban MJ, Warrington KJ. Evaluation for clinical predictors of positive temporal artery biopsy in giant cell arteritis. J Oral Maxillofac Surg. 2011;69(1):36-40.

20. González-López JJ, González-Moraleja J, Burdaspal-Moratilla A, Rebolleda G, Núñez-Gómez-Álvarez MT, Muñoz-Negrete FJ. Factors associated to temporal artery biopsy result in suspects of giant cell arteritis: a retrospective, multicenter, case-control study. Acta Ophthalmol. 2013;91(8):763-8.

21. El-Dairi MA, Chang L, Proia AD, Cummings TJ, Stinnett SS, Bhatti MT. Diagnostic Algorithm for Patients With Suspected Giant Cell Arteritis. J Neuroophthalmol. 2015;35(3):246-53.

22. Grossman C, Barshack I, Koren-Morag N, Ben-Zvi I, Bornstein G. Baseline clinical predictors of an ultimate giant cell arteritis diagnosis in patients referred to temporal artery biopsy. Clin Rheumatol. 2016;35(7):1817-22.

23. Toren A, Weis E, Patel V, Monteith B, Gilberg S, Jordan D. Clinical predictors of positive temporal artery biopsy. Can J Ophthalmol. 2016;51(6):476-481.

24. Ing EB, Lahaie Luna G, Toren A, Ing R, Chen JJ, Arora N, Torun N, Jakpor OA, Fraser JA, Tyndel FJ, Sundaram AN, Liu X, Lam CT, Patel V, Weis E, Jordan D, Gilberg S, Pagnoux C, Ten Hove M. Multivariable prediction model for suspected giant cell arteritis: development and validation. Clin Ophthalmol. 2017;11:2031-2042.

25. Weis E, Toren A, Jordan D, Patel V, Gilberg S. Development of a predictive model for temporal artery biopsies. Can J Ophthalmol. 2017;52(6):599-605.

26. Ing EB, Miller NR, Nguyen A, Su W, Bursztyn LLC, Poole M, Kansal V, Toren A, Albreki D, Mouhanna JG, Mulaodzanov A, Bernier M, Gans M, Lee D, Wendel C, Sheldon C, Shields M, Bellan L, Lee-Wing M, Mohadjer Y, Nijhawan N, Tyndel F, Sundaram ANE, Ten Hove MW, Chen JJ, Rodriguez AR, Hu A, Khalidi N, Ing R, Wong SWK, Torun N. Neural network and logistic regression diagnostic prediction models for giant cell arteritis: development and validation. Clin Ophthalmol. 2019;13:421-430.

27. González-López JJ, González-Moraleja J, Rebolleda G, Muñoz-Negrete FJ. A calculator for temporal artery biopsy result prediction in giant cell arteritis suspects. Eur J Intern Med. 2014 Oct;25(8):e98-e100.
28. Laskou F, Coath F, Mackie SL, Banerjee S, Aung T, Dasgupta B. A probability score to aid the diagnosis of suspected giant cell arteritis. Clin Exp Rheumatol. 2019;37 Suppl 117(2):104-108.

29. Sebastian A, Tomelleri A, Kayani A, Prieto-Pena D, Ranasinghe C, Dasgupta B. Probability-based algorithm using ultrasound and additional tests for suspected GCA in a fast-track clinic. RMD Open. 2020;6(3):e001297.

30. Monti S, Ponte C, Pereira C, Manzoni F, Klersy C, Rumi F, Carrara G, Hutchings A, Schmidt WA, Dasgupta B, Caporali R, Montecucco C, Luqmani R. The impact of disease extent and severity detected by quantitative ultrasound analysis in the diagnosis and outcome of giant cell arteritis. Rheumatology (Oxford). 2020;59(9):2299-2307.

31. Walvick MD, Walvick MP. Giant cell arteritis: laboratory predictors of a positive temporal artery biopsy. Ophthalmology. 2011;118(6):1201-4.

32. Kermani TA, Schmidt J, Crowson CS, Ytterberg SR, Hunder GG, Matteson EL, Warrington KJ. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum. 2012;41(6):866-71.

33. Soriano A, Muratore F, Pipitone N, Boiardi L, Cimino L, Salvarani C. Visual loss and other cranial ischaemic complications in giant cell arteritis. Nat Rev Rheumatol. 2017 Aug;13(8):476-484.

34. van der Geest KSM, Borg F, Kayani A, Paap D, Gondo P, Schmidt W, Luqmani RA, Dasgupta B. Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia. Ann Rheum Dis. 2020;79(3):393-399.

35. Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J. How to diagnose axial spondyloarthritis early. Ann Rheum Dis. 2004;63(5):535-43.

36. Sanders SL, Rathbone J, Bell KJL, Glasziou PP, Doust JA. Systematic review of the effects of care provided with and without diagnostic clinical prediction rules. Diagn Progn Res. 2017 Apr 26;1:13. doi: 10.1186/s41512-017-0013-2.

37. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jiménez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, Äinle FN, Prandoni P, Pruszczczyk P, Righini M, Torbicki A, Van Belle E, Zamorano JL; The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J. 2019 Oct 9;54(3).